Bonvicini, C
Faraone, S V
Scassellati, C
Article History
Received: 13 November 2015
Revised: 9 February 2016
Accepted: 1 April 2016
First Online: 24 May 2016
Competing interests
: In the past year, Dr Faraone received income, potential income, travel expenses and/or research support from Arbor, Pfizer, Ironshore, Shire, Akili Interactive Labs, CogCubed, Alcobra, VAYA Pharma, Neurovance, Impax, NeuroLifeSciences. With his institution, he has US patent US20130217707 A1 for the use of sodium-hydrogen exchange inhibitors in the treatment of ADHD. The remaining authors declare no conflict of interest.